Targeted delivery of radioactive treatment to improve bone marrow health
Official title: Selective Radionuclide Delivery for Precise Bone Marrow Niche Alterations
Funded at Fred Hutchinson Cancer Center · NIH-10883759 · Data updated 2026-11-12
This study is looking at a new way to use targeted radiation therapy to help your bone marrow heal better after treatments like radiation or chemotherapy, so you can produce healthy blood cells with less damage and side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | July 5, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $190,863 |
| NIH project number | 5R21CA283589-02 |
| Project ID | NIH-10883759 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with blood cancers who are receiving radiation therapy and may experience bone marrow damage.
✕Less likely to help
Patients with solid tumors or those not undergoing radiation therapy may not benefit from this research.
What this research studies
This research investigates how targeted radiation therapy can be used to improve the health of the bone marrow niche, which is crucial for producing blood cells. The approach involves using specific antibodies linked to radioactive isotopes to deliver treatment directly to the bone marrow, minimizing damage while enhancing recovery after radiation or chemotherapy. By understanding the effects of these treatments on the bone marrow environment, the research aims to develop strategies that reduce toxicity and improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for patients undergoing radiation therapy for blood cancers.
How similar studies have gone: Previous research has shown promise in using targeted radiation therapies for blood cancers, but the specific impact on the bone marrow niche remains largely untested.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Orozco, Johnnie Jose — Fred Hutchinson Cancer Center
- Study coordinator: Orozco, Johnnie Jose
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.